GlassScriptPhysician profile
Todd Feldman
NPI 1639655426
$2,259.91
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105 · 2022: $1,841 · 2023: $242 · 2024: $71.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $245 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.90 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $668.20 | 2021-2024 | |
| Amgen INC. | $442.84 | 2021-2023 | Otezla, Enbrel |
| Sun Pharmaceutical Industries INC. | $230.51 | 2022-2023 | |
| Lilly USA, LLC | $168.24 | 2022 | |
| Leo Pharma INC. | $112.95 | 2022 | |
| Janssen Biotech, INC. | $112.32 | 2022 | |
| Galderma Laboratories, L.P. | $102.95 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $78.36 | 2022 | |
| Ucb, INC. | $74.28 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.59 | 2022-2023 | Spevigo |
| Pfizer INC. | $44.29 | 2022 | |
| Novartis Pharmaceuticals Corporation | $43.08 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $29.68 | 2021 | |
| Epi Health, LLC | $24.99 | 2022 | |
| Incyte Corporation | $23.65 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $21.61 | 2022 | |
| Dermavant Sciences, INC. | $16.58 | 2022 | |
| Kyowa Kirin, INC. | $13.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.